Baidu
map

Clin Genitourin Cancer:前列腺癌发病率和死亡率与前列腺癌家族史的关系

2020-07-13 MedSci原创 MedSci原创

本研究旨在确定一级亲属(FDR)中的前列腺癌家族史与前列腺癌的发病率和死亡率之间的关系。

本研究旨在确定一级亲属(FDR)中的前列腺癌家族史与前列腺癌的发病率和死亡率之间的关系。

 

研究人员查阅了在前列腺、肺、结直肠和卵巢(PLCO)试验中招募的未知男性数据集。纳入有关FDR中具有前列腺癌家族史的完整信息的男性。在多变量Cox回归模型中评估了家族史对前列腺癌发病率和死亡率的影响。同样,评估了FDR数量对前列腺癌的影响以及FDR的最小诊断年龄对前列腺癌的影响。

 

结果,当前分析中总共包括74,781名参与者,其中包括FDR中有前列腺癌家族史的5281名参与者和FDR中没有前列腺癌家族史的69,500名参与者。在FDR中没有前列腺癌家族史的参与者中,随后总共诊断出7450名患者(10.5%)患有前列腺癌。而在FDR中具有前列腺癌家族史的患者中,随后总共诊断出889例前列腺癌患者(16.5%)。

 

校正后的多元Cox回归模型分析显示,前列腺癌家族史与较高的前列腺癌诊断率相关(危险比[HR]为1.590; 95%置信区间[CI]为1.482-1.705;P <.001)。患有前列腺癌的FDR数量与较高的前列腺癌发生率成比例相关(HR,1.529;95%置信区间[CI],1.439-1.624;P <.001)。FDR中前列腺癌的家族史不能预测PLCO筛查(干预)组中较高的前列腺癌死亡率(HR,0.829; 95%CI,0.422-1.629; P = .587),而可以预测较高的前列腺癌PLCO非筛查(对照)组的癌症死亡率(HR,1.894; 95%CI,1.154-3.109;P = 0.012)。前列腺癌FDR的数量与PLCO筛查(干预)臂中较高的前列腺癌死亡率无关(HR,0.956;95% CI,0.541-1.691;P = .878),而与PLCO非筛查(对照)臂中较高的前列腺癌死亡率有关(HR,1.643;95% CI,1.083-2.493;P = .020)。

 

综上所述,该研究结果表明,前列腺癌的家族史与患者总体队列中前列腺癌诊断的风险增加以及非筛查亚队列中前列腺癌死亡的较高风险有关。有必要对选定的高风险人群(包括有悠久家族史的人群)进行筛查的作用进行前瞻性评估。

 

原始出处:

 

Omar Abdel-Rahman. Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial. Clin Genitourin Cancer. 2019 Aug;17(4):e837-e844. doi: 10.1016/j.clgc.2019.05.015.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823646, encodeId=4bdb1823646e9, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Apr 25 18:01:45 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799880, encodeId=5beb1e9988075, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Apr 06 05:01:45 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079280, encodeId=b83420e92807c, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri May 21 08:01:45 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479812, encodeId=27a614e981236, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jul 14 16:01:45 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040781, encodeId=732a1040e8183, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 13 04:01:45 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823646, encodeId=4bdb1823646e9, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Apr 25 18:01:45 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799880, encodeId=5beb1e9988075, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Apr 06 05:01:45 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079280, encodeId=b83420e92807c, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri May 21 08:01:45 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479812, encodeId=27a614e981236, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jul 14 16:01:45 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040781, encodeId=732a1040e8183, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 13 04:01:45 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823646, encodeId=4bdb1823646e9, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Apr 25 18:01:45 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799880, encodeId=5beb1e9988075, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Apr 06 05:01:45 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079280, encodeId=b83420e92807c, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri May 21 08:01:45 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479812, encodeId=27a614e981236, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jul 14 16:01:45 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040781, encodeId=732a1040e8183, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 13 04:01:45 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823646, encodeId=4bdb1823646e9, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Apr 25 18:01:45 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799880, encodeId=5beb1e9988075, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Apr 06 05:01:45 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079280, encodeId=b83420e92807c, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri May 21 08:01:45 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479812, encodeId=27a614e981236, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jul 14 16:01:45 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040781, encodeId=732a1040e8183, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 13 04:01:45 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1823646, encodeId=4bdb1823646e9, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Apr 25 18:01:45 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799880, encodeId=5beb1e9988075, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Tue Apr 06 05:01:45 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079280, encodeId=b83420e92807c, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri May 21 08:01:45 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479812, encodeId=27a614e981236, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jul 14 16:01:45 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040781, encodeId=732a1040e8183, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jul 13 04:01:45 CST 2020, time=2020-07-13, status=1, ipAttribution=)]
    2020-07-13 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Eur Urol:BRCA2基因组区域的前列腺癌风险评估

最近,有研究人员提出了BRCA2前列腺癌集中区域(c.7914到3'),在该区域,致病性变异(PVs)于前列腺癌(PCa)风险相关,并且比BRCA2基因任何区域的PVs的风险都高。

Exp Cell Res:胰岛素能够加重前列腺上皮细胞中高糖诱导的上皮间质转化

2型糖尿病(T2DM)和良性前列腺增生(BPH)是两种最常见的老龄化恶性疾病,且具有内分泌和代谢疾病的特征。

Brit J Cancer:抗PD-L1免疫治疗和放疗联用对肿瘤免疫微环境的影响

放疗能够增强先天性和适应性抗肿瘤免疫。然而,并不清楚该效应能否通过免疫治疗和放疗联用治疗前列腺癌来增强。最近,有研究人员调查了预临床前列腺癌模型对放疗的肿瘤免疫微环境响应情况,并检测了是否放疗诱导的肿

Eur Urol:保留Retzius的机器人辅助根治性前列腺切除术可持久地改善泌尿功能和生活质量且不会减弱肿瘤疗效

之前的研究表明,保留Retzius的机器人辅助根治性前列腺切除(RS-RARP)能够改善尿失禁。然而,关于技术和结果和可行性和普遍性仍旧存在问题。最近,有研究人员比较了140例连续的标准机器人辅助根治

Oncogene:AR和ERG能够促使前列腺癌特异性长非编码RNAs的表达

长非编码RNAs(lncRNAs)在癌症发展和恶化过程中具有关键的作用,并且一些功能是高度癌症特异性的。然而,它们表达的原因是否是一种特异的调控机制的结果或者是基因组重组引起的非特异性转录结果仍旧不清

Eur Urol:转移去势抵抗性前列腺癌男性双相雄激素治疗的多队列开放标签II期试验

循环高剂量睾酮注射治疗,也被称为双相雄激素治疗(BAT),是转移去势抵抗性前列腺癌(mCRPC)男性患者的一种新的治疗策略。BAT在起始的研究中表现出了临床活性,也许能够恢复对雄激素受体(AR)靶向治

Baidu
map
Baidu
map
Baidu
map